Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735217 | 0.94 | CYP2C9 (0.51) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6231131 | 0.93 | CYP2C9 (0.54) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6234881 | 0.92 | MAPK1 (0.50) | CYP2C9MAPK1HSD17B10NR1I2XDH | |
| SCHEMBL6233730 | 0.89 | CYP2C9 (0.53) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6733019 | 0.89 | CYP2C9 (0.51) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6738002 | 0.89 | CYP2C9 (0.62) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6207951 | 0.88 | MAPK1 (0.58) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6232557 | 0.84 | CYP2C9 (0.64) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL6742171 | 0.83 | CYP2C9 (0.64) | CYP2C9MAPK1HSD17B10NR1I2 | |
| SCHEMBL1522950 | 0.83 | MAPK1 (0.47) | CYP2C9MAPK1HSD17B10NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | claimed |
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | CYP2C9 1218/4885MAPK1 3699/4885HSD17B10 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.